^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    perillyl alcohol (NEO100)

    i
    Other names: NEO100, POH, NEO-100
    Company:
    NeOnc Technologies
    Drug class:
    Apoptosis stimulant, RAS inhibitor
    Related drugs:
    1d
    A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Neonc Technologies, Inc. | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    perillyl alcohol (NEO100)
    4ms
    Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma (clinicaltrials.gov)
    P1/2, N=49, Recruiting, Neonc Technologies, Inc. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    perillyl alcohol (NEO100)
    8ms
    Therapeutic Delivery of circDYM by Perillyl Alcohol Nanoemulsion Alleviates LPS-Induced Depressive-Like Behaviors. (PubMed, Adv Sci (Weinh))
    This effect is achieved by reducing the CD11b+CD45dim microglia population and iNOS expression, restoring the expression of protein-95 (PSD-95) and synaptophysin. These findings indicated that PANE represents an efficient platform for delivering circRNAs to the brain, and intranasal administration of PANE2-4-circDYM is a promising strategy for ameliorating LPS-induced depressive-like behaviors.
    Journal
    |
    ITGAM (Integrin, alpha M) • SYP (Synaptophysin)
    |
    perillyl alcohol (NEO100)
    9ms
    Patient with recurrent grade 4 astrocytoma responding favorably to intranasal delivery of NEO100, highly pure perillyl alcohol: illustrative case. (PubMed, J Neurosurg Case Lessons)
    The authors present a case in which IN cancer therapy with NEO100 was well tolerated and was associated with striking tumor regression, providing further evidence that this novel conceptual approach to cancer therapy might become useful for the improved treatment of recurrent glioma. https://thejns.org/doi/10.3171/CASE24683.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    temozolomide • perillyl alcohol (NEO100)
    1year
    Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma (clinicaltrials.gov)
    P1/2, N=49, Recruiting, Neonc Technologies, Inc. | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    perillyl alcohol (NEO100)
    1year
    A Study of the Safety, Dosing, and Delivery of NEO100 in Patients with Pediatric Brain Tumors (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Neonc Technologies, Inc. | Trial completion date: Oct 2024 --> Oct 2025 | Initiation date: May 2024 --> Dec 2024 | Trial primary completion date: Oct 2024 --> Oct 2025
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    perillyl alcohol (NEO100)
    over1year
    Molecular pharmacology and therapeutic advances of monoterpene perillyl alcohol. (PubMed, Phytomedicine)
    This review systematically summarizes the recent advances in POH and highlights its therapeutic effects and potential mechanisms as well as the clinical settings, which is helpful to develop POH into functional food and new candidate drug for prevention and management of diseases. Future studies are needed to conduct more biological activity studies of POH and its derivatives, and check their clinical efficacy and potential side effects.
    Review • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • NLRP3 (NLR Family Pyrin Domain Containing 3) • NOS3 (Nitric oxide synthase 3)
    |
    perillyl alcohol (NEO100)
    over1year
    A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Neonc Technologies, Inc.
    New P1 trial
    |
    perillyl alcohol (NEO100)
    2years
    Inhibition of autophagy and induction of glioblastoma cell death by NEO214, a perillyl alcohol-rolipram conjugate. (PubMed, Autophagy)
    When combined with chloroquine and TMZ, the anticancer impact of NEO214 is further potentiated and unfolds against TMZ-resistant cells as well. Taken together, our findings characterize NEO214 as a novel autophagy inhibitor that could become useful for overcoming chemoresistance in glioblastoma.Abbreviations: ATG: autophagy related; BAFA1: bafilomycin A; BBB: blood brain barrier; CQ: chloroquine; GBM: glioblastoma; LAMP1: lysosomal associated membrane protein 1; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MGMT: O-6-methylguanine-DNA methyltransferase; MTOR: mechanistic target of rapamycin kinase; MTORC: MTOR complex; POH: perillyl alcohol; SQSTM1/p62: sequestosome 1; TFEB: transcription factor EB; TMZ: temozolomide.
    Journal
    |
    SQSTM1 (Sequestosome 1) • LAMP1 (Lysosomal Associated Membrane Protein 1) • TFEB (Transcription Factor EB 2)
    |
    temozolomide • sirolimus • perillyl alcohol (NEO100)
    almost3years
    Enhanced brain entry of checkpoint-inhibitory therapeutic antibodies facilitated by intraarterial NEO100 in mouse models of brain-localized malignancies. (PubMed, J Neurosurg)
    BBB opening by IA NEO100 facilitates brain tumor access by checkpoint-inhibitory antibodies and enables their therapeutic activity, along with increased levels of T-cell recruitment.
    Preclinical • Journal • Checkpoint inhibition
    |
    CD8 (cluster of differentiation 8)
    |
    perillyl alcohol (NEO100)
    3years
    Safety and Efficacy Study in Recurrent Grade IV Glioma (clinicaltrials.gov)
    P1/2, N=49, Recruiting, Neonc Technologies, Inc. | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Jun 2022 --> Jun 2024
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    perillyl alcohol (NEO100)
    4years
    Safety and Efficacy Study in Recurrent Grade IV Glioma (clinicaltrials.gov)
    P1/2, N=49, Recruiting, Neonc Technologies, Inc. | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    perillyl alcohol (NEO100)